Johnson & Johnson vs Abbott Laboratories: Diverging Strategic Paths in Healthcare
Johnson & Johnson (JNJ) is focusing on its Innovative Medicine segment with strong revenue growth from oncology drugs like DARZALEX and TREMFYA, while Abbott Laboratories (ABT) has expanded through the $21 billion acquisition of Exact Sciences. JNJ's Q1 earnings showed a 11.2% increase in Innovative Medicine sales, whereas ABT’s Q2 results were driven by FreeStyle Libre growth and Cologuard contributions.